Skip to main content

Table 4 Factors associated with a positive anti-HBs level – results of multivariable models (N = 2,489)

From: Prevalence of vaccine-derived hepatitis B surface antibodies in children and adolescents in Germany: results from a population-based survey, 2014–2017

 

Anti-HBs level ≥ 10 IU/L

Anti-HBs level ≥ 100 IU/L

OR

95% CI

OR

95% CI

Model 1 (Recommended schedule (≥ 3 doses))

 Recommended schedule (≥ 3 doses)

  Yes

0.92

0.65–1.32

1.16

0.79–1.70

  No

Reference

Reference

 Time since last vaccination dose (in years)

0.85

0.82–0.88

0.83

0.79–0.86

 Type of vaccine

  Infanrix Hexa

Reference

Reference

  Hexavac

0.44

0.30–0.64

0.38

0.21–0.72

  Monovalent

1.38

0.98–1.96

2.06

1.42–2.99

Model 2; 3 versus 4 doses (Recommended schedule (≥ 3 doses))

 3 versus 4 doses

  3 doses

Reference

Reference

  4 doses

1.44

0.81–2.60

1.06

0.60–1.85

 Time since last vaccination dose (in years)

0.85

0.82–0.89

0.83

0.79–0.86

 Type of vaccine

  Infanrix Hexa

Reference

Reference

  Hexavac

0.47

0.31–0.69

0.42

0.20–0.85

  Monovalent

1.95

1.06–3.57

2.11

1.23–3.63